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Objectives: The contribution of the lymphatic system to tumor metastasis is being 
increasingly appreciated through studies of human cancers. As the biological behavior 
of nasopharyngeal carcinoma (NPC) depends on its nodal status, patients with 
advanced nodal status show a higher tendency toward a poor outcome. Here, we 
examined the role of lymphangiogenesis on lymphatic spread of NPC. We also evaluated 
the involvement of vascular endothelial growth factor (VEGF)-C/VEGF receptor 3 
(VEGFR3) signaling pathway on lymphangiogenesis in NPC. Furthermore, we tested 
whether Epstein-Barr virus (EBV)-latent membrane protein (LMP) 1 induces VEGF-C. 
Materials and Methods: Forty-one patients with NPC were evaluated for expressions of 
VEGF-C and its receptor, VEGFR3, and LMP1 proteins and lymphatic vessel counts 
(LVC) highlighted by anti-podoplanin employing immunohistochemistry. The VEGF-C 
induction by LMP1 was then tested with Western blotting and enzyme-linked 
immunosorbent assay in vitro. 
Results: The LVC and VEGF-C expression were significantly higher in cases with 
advanced regional lymph node metastasis (N2,3) than those with no or limited lymph 
node involvement (N0,1) (p = 0.0380 and p = 0.0109, respectively). In 
VEGF-C/VEGFR3-positive cases, the LVC were significantly increased compared with 
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VEGF-C/VEGFR3-negative cases (p = 0.0007). However, LMP1 expression did not show 
significant associations with LVC and VEGF-C-expression scores (p = 0.1210 and p = 
0.1324, respectively). Induction of VEGF-C protein by LMP1 was not detected in vitro. 
Conclusions: These results suggest the involvement of the VEGF-C/VEGFR3 axis in the 
induction of lymphangiogenesis which results in lymphatic spread of NPC. However, 
EBV-LMP1 was not associated with the mechanism. 
 
Key Words: Lymphangiogenesis, lymph node metastasis, vascular endothelial growth 
factor-C, vascular endothelial growth factor receptor 3, nasopharyngeal carcinoma, 




     Seventy-five percent of patients with nasopharyngeal carcinoma (NPC) have 
regional lymph node involvement at diagnosis [1]. Even early primary tumors are often 
associated with advanced regional lymph node metastasis. As the biological behavior of 
NPC depends on its nodal status, patients with advanced nodal status have a higher 
tendency toward a poor outcome [2]. Another distinctive character of NPC is the 
consistent association with Epstein-Barr virus (EBV). EBV is considered to be strongly 
associated with the carcinogenesis of NPC [3].  
Angiogenesis, the growth of new capillaries from pre-existing blood vessels, is 
essential for cancers to grow beyond minimal size [4]. Tumor angiogenesis is induced by 
increased secretion of angiogenic factors and by down-regulation of angiogenic 
inhibitors [5]. Previously, we showed a significant relationship between angiogenesis and 
advancement of nodal status in NPC tissues [6, 7]. Furthermore, we reported that latent 
membrane protein 1 (LMP1), an EBV-associated oncoprotein, induces angiogenic factors 
including vascular endothelial growth factor (VEGF)-A, interleukin (IL)-8, and 
fibroblast growth factor (FGF)-2 [6-8]. Thus, LMP1 plays a central role in angiogenesis, 
which results in progression of lymph node metastasis in NPC. 
     The contribution of the lymphatic system to tumor metastasis is being 
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increasingly appreciated through studies of human cancers, such as carcinoma of the 
breast, colon, and prostate as well as melanoma [9-12]. Tumor cells enter the lymphatic 
vasculature by invading pre-existing peritumoral lymphatic vessels or by eliciting 
lymphangiogenesis via growth factor production [11, 13, 14]. The density of lympatic 
vessels correlates with the progression of lymph node metastasis and poor outcome in 
some human cancers [10, 15]. One of the lymphangiogenic growth factors, named VEGF-C, 
that signals through its receptor, VEGF receptor 3 (VEGFR3), has been discovered. 
VEGF-C-expressions in tumor tissues have been shown to promote lymphangiogenesis 
through signaling of VEGFR3 expressed on lymphatic endothelial cells, which results in 
the lymphatic spread of the tumor cells [16-21]. 
     Here, we counted the tumor lymphatic vessels, using podoplanin as a lymphatic 
marker, and examined its relationship with lymph node metastasis in NPC. We tested 
the presence of the VEGF-C/VEGFR3 pathway and its role in the increasing number of 
lymphatic vessels and lymph node metastasis using NPC tissues. The impact of 
EBV-LMP1 on lymphangiogenesis was also evaluated in NPC, and the induction of 




Materials and Methods 
Tissue samples. 
     Forty-one specimens were obtained from patients with NPC who underwent 
biopsy at Kanazawa University Hospital or Toyama Prefectural Central Hospital 
between 2000 and 2009. All specimens were fixed in 10% neutral formalin and 
embedded in paraffin. After a review of all H&E-stained slides of the specimens, they 
were classified into three histopathological groups. These were composed of 3 squamous 
cell carcinomas (WHO type I), 14 nonkeratinizing carcinomas (WHO type II), and 24 
undifferentiated carcinomas (WHO type III). The clinical staging of NPC was evaluated 
based on the tumor-node metastasis classification of the Union Internationale Contre le 
Cancer. Pretreatment staging of N factor was performed with high-resolution computed 
tomography and/or 18F-fluorodeoxy-glucose positron emission tomography before 
starting the primary treatment. 
 
Immunohistochemical analysis. 
     Consecutive 4-m sections were cut from each block. Immunohistochemical 
staining was performed as described previously [7, 22]. The following antibodies were 
used as primary antibodies: monoclonal antibodies for podoplanin (dilution 1:100) and 
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LMP1 derived from mouse (dilution 1:50) (DAKO, USA), polyclonal antibody for 
VEGF-C derived from rabbit (dilution 1:100) (Invitrogen, USA), and polyclonal antibody 
for VEGFR3 derived from goat (dilution 1:50) (R&D systems, USA). The sections were 
color-developed with substrate/chromogen diaminobenzidine (DAKO, Copenhagen, 
Denmark). The sections were counterstained with hematoxylin. NPC specimens that 
had been used in previous studies [7, 22], normal lymph node, human placental tissue, 
and human melanoma specimens were used as positive controls for LMP1, podoplanin, 
VEGF-C, and VEGFR3 proteins, respectively. The specificity of staining was confirmed 
using non-immune serum instead of the primary antibody as a negative control. 
 
Evaluation of immunohistochemical staining for VEGF-C, VEGFR3, and LMP1 
proteins. 
     The stained sections were independently examined by two authors (K. H. and N. 
W.). In each case, two arbitrary separate microscopic fields (200x) containing >200 
tumor cells were evaluated. After counting both immunoreactive cells and the total 
number of tumor cells, the average percentages of immunoreactive cells were calculated 
without knowledge of the clinical data. 
     The results for VEGF-C protein were classified into scores from 0 to 10, depending 
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on the percentage of immunoreactive tumor cells: score 0, 0%; score 1, >0% and ≦10%; 
score 2, >10% and ≦20%; score 3, >20% and ≦30%; score 4, >30% and ≦40%; score 5, 
>40% and ≦50%; score 6, >50% and ≦60%; score 7, >60% and ≦70%; score 8, >70% 
and ≦80%; score 9, >80% and ≦90%; score 10, >90% and ≦100%. The data for LMP1 
protein were classified into negative or positive, depending on the percentage of 
immunoreactive tumor cells: negative, <10%; positive, ≧10%[22]. 
     The finding for VEGFR3-staining was considered positive whenever the vessel 
structures in the tumor stroma were highlighted. When the authors could not find any 
vessel structure highlighted in the tumor stroma, the specimen was considered 
negative. 
     VEGF-C, a member of the VEGF family of secreted glycoprotein, is a ligand of 
VEGFR3. We postulated that VEGF-C secreted by tumor cells stimulates 
lymphangiogenesis through binding with VEGFR3 expressed on lymphatic vessels in 
NPC. Thus, we need to evaluate the association of the set of VEGF-C and VEGFR3 
expression with the lymphatic vessel counts or the progression of lymph node 
metastasis. To analyze the associations of VEGF-C/VEGFR3 axis with lymphatic vessel 
counts or regional lymph node status, VEGF-C/VEGFR3 expressions were classified 
into two categories, depending on the percentage of immunoreactive tumor cells: 
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VEGF-C/VEGFR3-negative, VEGF-C-expression score <5 and VEGFR3-negative; and 
VEGF-C/VEGFR3-positive, either VEGF-C-expression ≧5 or VEGFR3-positive. 
 
Lymphatic vessel counting. 
     Lymphatic vessels were highlighted by staining lymphatic endothelial cells with 
anti-podoplanin antibody. The area of highest lymphvascular density was found by light 
microscopy in a 10x field followed by counting in a 200x field. Any lymphatic endothelial 
cell or endothelial cluster staining positive for podoplanin that was clearly separate 
from adjacent lymphatic vessels was considered to be a single, countable vessel. Results 
were expressed as the highest number of lymphatic vessels identified within any single 
200x field. 
 
Plasmids, cell line, and transient transfection. 
     A pcDNA3-based LMP1-expression plasmid (pcLMP1) has been described 
previously [23]. Ad-AH cells are an EBV-negative human nasopharyngeal epithelial cell 
line [24]. Cells were maintained in DMEM with 10% fetal bovine serum, penicillin, and 
streptomycin. For Western blot analysis, cells were transfected with 1.0g of the 
appropriate plasmids using the Effectene transfection kit (QIAGEN) in accordance with 
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manufacturer’s instruction. Forty-eight hours after transfection, Ad-AH cells were held 
for 24 hours in DMEM with neither fetal bovine serum nor antibiotics. 
 
Western blot analysis for VEGF-C and LMP1 proteins. 
     Whole-cell lysates were extracted in 100 l radioimmunoprecipitation assay buffer 
[50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1% Nonidet P-40, 
0.5% Na deoxycholate, 0.1% SDS, 25 mmol/L DTT, 0.2 mmol/L Na orthovanadate, 100 
mmol/L NaF, 1 mmol/L phenylmethylsulfonyl fluoride], and the protein concentration 
was determined by a Bio-Rad protein assay. Each cell lysate (100 g) was solubilized for 
10% SDS-PAGE and transferred to nitrocellulose membranes (Amersham) by ATTO 
semidry transfer apparatus. The membrane was incubated with an antibody to VEGF-C 
(dilution 1:100) (Invitrogen, USA), or LMP1 (dilution 1:100) (DAKO, USA) protein at 
4℃ overnight. -tubulin was used as the loading control. 
 
Enzyme-linked immunosorbent assay (ELISA). 
     Ad-AH cells transfected with pcDNA3 with or without pcLMP1 were cultured with 
serum-free DMEM for 24 h. The VEGF-C content of the supernatants was then 






     The data were analyzed with Stat View software (Abacus Concepts, Berkley, CA). 
Correlations between the VEGF-C-expression scores and the lymphatic vessel counts 
were evaluated by Spearman’s rank test. The progression of N factor and the 
expressions of VEGFR3 and LMP1 proteins in relation to the lymphatic vessel counts 
and also the LMP1-expression in relation to VEGF-C-expression were analyzed using 
the Mann-Whitney U test. Associations among progression of N factor and the 
expressions of LMP1, VEGF-C or VEGFR3 proteins were analyzed with Fisher’s exact 




Expressions of podoplanin, VEGF-C, VEGFR3, and LMP1 in NPC tissues. 
     Podoplanin-expression was essentially restricted to thin-walled vessel structures 
but was occationally seen in tissue macrophages and in some connective tissues. Most 
lymphatic vessels highlighted by podoplanin-staining were detected as scattered in 
tumor cell nests at the tumor stroma (Figure 1A). In NPC tissues, VEGF-C-expression 
was observed as cytoplasmic staining in tumor cells (Figure 1B). In the stroma of the 
NPC tissues, VEGFR3-positive lymphatic vessels with small diameters could be 
observed (Figure 1C). LMP1 was localized at the cytoplasm and the cell membrane of 
the tumor cells (Figure 1D). 
     Detailed results showing the lymphatic vessel counts and VEGF-C scores in 
relation to the clinicopathological data are summarized in Additional Table S1. 
Lymphatic vessel counts in relation to progression of N factor are shown in Table 1. The 
N classification was subdivided into two categories (N0,1 and N2,3). In 16 cases with 
advanced lymph node metastasis category (N2,3), the mean lymphatic vessel count was 
significantly higher than in twenty-five cases of the N0,1-category (p = 0.0380). A 
significant relationship was observed between VEGF-C-expression scores and 
lymphatic vessel counts (p = 0.0114) (Figure 2), which suggests that expression of 
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VEGF-C protein is closely associated with lymphangiogenesis in NPC. 
VEGFR3-positive cases had significantly higher lymphatic vessel counts than 
VEGFR3-negative cases (p = 0.0012) (Table 1). When VEGF-C/VEGFR3-positive cases 
were compared with VEGF-C/VEGFR3-negative cases, the lymphatic vessel counts 
were significantly higher in VEGF-C/VEGFR3-positive cases (p = 0.0007) (Table 1).  
VEGF-C-positive cases showed also significant progression in N factor compared 
with negative cases (p = 0.0109) (Table 2). Positive VEGFR3 protein expression showed 
a trend toward more advanced N factor-progression, but the result did not achieve 
statistical significance (p = 0.0965) (Table 2). However, VEGF-C/VEGFR3-positive cases 
showed significant progression of N factor compared with VEGF-C/VEGFR3-negative 
category (p = 0.0285) as shown in Table 2. These results suggest that the VEGF-C and 
its ligand, VEGFR3, -associated pathway is closely related with the progression of 
lymph node metastasis in NPC.  
Associations between LMP1 expression and progression of N factor is also shown 
in Table 2. In LMP1-positive cases, N factor was more significantly progressed than in 
LMP1-negative cases (p = 0.0057) (Table 2), which was consistent with our previous 
reports [7, 22]. Association between LMP1-expression, and lymphatic vessel counts and 
VEGF-C-expression are shown in Table 3. Although LMP1-positive cases tended to 
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show higher numbers of lymphatic vessels and higher VEGF-C-expression scores, the 
differences were not statistically significant (p = 0.1210 and p = 0.1324, respectively) 
(Table 3).  
These results suggest a significant role of VEGF-C/VEGFR3 axis in the 
progression of N factor through induction of lymphangiogenesis in NPC. However, the 
role of LMP1 in induction of lymphangiogenesis was not identified as a result of 
immunohistochemical analysis using NPC tissues. 
 
Expression of VEGF-C protein was not induced by LMP1 in vitro. 
     We previously showed the induction of comprehensive set of cellular factors that 
mediates steps in the process of invasion and metastasis of tumor cells, as well as 
angiogenesis. Contrary to our expectations, in the immunohistochemical study using 
NPC tissues, we could not show an association between expressions of LMP1 and 
VEGF-C proteins. To confirm whether LMP1 is really irrelevant in the induction of 
VEGF-C expression, we investigated whether LMP1 protein could induce VEGF-C 
protein production in vitro.  
Ad-AH cells were transiently transfected with pcDNA3 with or without pcLMP1. 
VEGF-C protein was detected by Western blot analysis of whole-cell extract. As shown 
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in Figure 3A, VEGF-C protein expression was not upregulated by increasing the 
amount of LMP1 protein expression. We also examined the VEGF-C-concentration in 
supernatant from Ad-AH cells transfected with pcDNA3 with or without pcLMP1 by 
ELISA. As shown in Figure 3B, the concentrations of VEGF-C in supernatant were 
similar between cells with or without pcLMP1-transfection. These results support the 
data from immunohistochemical analysis that LMP1 is irrelevant in 
VEGF-C-expression in NPC tissues. 
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Discussion   
A close relationship between tumor angiogenesis and regional lymph node 
metastasis has been shown in malignant tumors [25-27]. Increased tumor angiogenesis 
may have an indirect influence on nodal metastasis by increasing the number of cells 
entering the blood. Tumor cells then pass through the junctions between blood and 
lymphatic circulations and can be arrested in the lymph node. Previously, we reported a 
relationship between angiogenesis and the progression of regional lymph node 
metastasis in NPC [6, 22]. We also showed that an EBV-encoded oncoprotein, LMP1, plays 
a key role in anigiogenesis through the induction of angiogenic factors including FGF-2, 
IL-8, and VEGF-A [6-8, 22, 28-30]. However, lymphangiogenesis studies have been limited by 
the lack of specific lymphatic endothelial markers. Recently, monoclonal antibody for 
podoplanin was shown in breast and tonsillar tissues to selectively detect lymphatic 
vessels [31, 32]. Thus, it has remained unresolved whether lymphangiogenesis can be 
related to lymph node metastasis in clinical NPC specimens. 
     A clinically detectable lymph node metastasis is the result of complex multistep 
processes, including the dissemination of tumor cells from the primary site to the 
lymphatic vessels, the transport of tumor cells through the lymphatic system to the 
lymph nodes, the settlement of tumor cells in lymph nodes, and the growth of the 
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metastatic lesion to a detectable mass [9]. Some retrospective analyses of human cancer 
samples have shown a positive correlation between tumoral lymphatics and lymph node 
metastasis [27, 33]. Tumor cells produce multiple lymphangiogenic factors that might 
stimulate tumor lymphangiogenesis. Various studies using animal tumor models have 
provided evidence that overexpression of VEGF-C in tumor cells can increase peri- 
and/or intratumoral lymphangiogenesis as evidenced by both increased lymphatic 
vessel density and/or diameter and enhanced proliferation rates in tumor-associated 
lymphatic vessels [11]. Thus, in the current study, as a preliminary report on the 
relationship between the lymphangiogenesis and the progression of N factor in NPC, we 
highlighted VEGF-C, which is expressed in the tumor cells, and its receptor, VEGFR3, 
of which the major site of expression is the lymphatic endothelium. We showed that 
counting the lymphatic vessels highlighted with anti-podoplanin antibody significantly 
correlated with the progression of N factor. Furthermore, we showed that the presence 
of VEGF-C/VEGFR3 axis in NPC tissues was significantly associated with both 
increasing lymphatic vessel counts and the progression of N factor. These results 
indicate that the VEGF-C/VEGFR3 axis (composed of tumor-secreted VEGF-C and 
VEGFR3-expression in lymphatic endothelial cells) is involved in the lymphatic spread 
of tumor cells through induction of lymphangiogenesis in NPC. 
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     Previously, VEGF-A was considered only a tumor angiogenesis factor, signaling 
through VEGFR2 and VEGFR1, which are expressed on tumor-associated blood vessels 
[34]. FGF-2 is an angiogenic molecule that has potent stimulatory activity on vascular 
endothelial cells in vitro and on angiogenesis in vivo [9, 35]. The role of cyclooxygenase 
(COX)-2 in promoting tumor-associated angiogenesis is also well documented [36]. 
However, Hirakawa et al. identified VEGF-A as a novel tumor lymphangiogenesis factor 
[37]. Chang, et al. reported that FGF-2 stimulates the proliferation, migration and tube 
formation of isolated lymphatic endothelial cells, indicating a direct role in lymphatic 
vessel growth [38]. In addition, COX-2 demonstrates a positive regulatory role in 
lymphangiogenesis [39]. Interestingly, all these factors are induced by the 
EBV-associated oncoprotein, LMP1, in NPC [8, 29, 30]. Thus, we expected that LMP1 
should have a key role in lymphoangiogenesis, as well as in angiogenesis, in NPC. 
However, we could not find a significant association between expression of LMP1 and 
lymphatic vessel counts in NPC tissues. In addition, although VEGF-C-expression was 
associated with both lymphatic vessel counts and the progression of N factor in NPC 
tissue, its expression was not associated with the expression of LMP1. We also failed to 
determine the upregulation of VEGF-C-production or -secretion by LMP1 in vitro at 
least at the protein level using Western blot analysis or ELISA. Thus, we conclude here 
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that EBV-LMP1 is not involved in the regulation of lymphangiogenesis in NPC. 
Although the detection of the key lymphangiogenesis regulator in NPC is beyond the 
scope of this paper, the roles of other lymphangiogenesis factors such as VEGF-D and 
platelet-derived growth factor-BB, and other EBV-associated proteins, such as LMP2A, 
need to be fully examined in the next step of our study. Tumor-associated macrophages 
producing lymphangiogenic factors such as VEGF-C and VEGF-D may also be of 
widespread significance.  
In conclusions, we reported here that the VEGF-C/VEGFR3 axis promotes lymph 
node metastasis through the induction of lymphangiogenesis in NPC. The mechanism of 
lymph node metastasis through lymphangiogenesis was independent of EBV-associated 
oncoprotein, LMP1, and was distinct from lymph node metastasis dependent on 
tumor-angiogenesis in which LMP1 plays a key role through the induction of angiogenic 
factors. The pathway for lymphangiogenesis-induction should be fully elucidated, 
because the mechanism could be a new target for therapies to suppress lymph node 
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Figure 1. Immunohistochemical detection of podoplanin (Original magnification, x200) 
(A), VEGF-C (Original magnification, x400) (B), VEGFR3 (Original magnification, 
x200) (C), and LMP1 (Original magnification, x200) (D) in NPC tissues. (A) Podoplanin 
expression was essentially restricted to vessel structures. Lymphatic vessels 
highlighted with anti-podoplanin detected as a scattered pattern were seen at the tumor 
stroma. (B) VEGF-C protein was localized at the tumor cytoplasms. (C) VEGFR3 was 
detected at the lymphatic endothelium at the stroma of the tumor nest. (D) LMP1 was 
recognized at the cytoplasm and cell membrane of the tumor cells. 
 
Figure 2. Correlation between VEGF-C score and lymphatic vessel counts in 41 cases of 
nasopharyngeal carcinoma. Shown is the plot of the lymphatic vessel counts according 
to the VEGF-C-expression score. Regression line: Lymphatic Vessel Counts (Y) = 7.209 + 
1.062 x VEGF-C Score (X). Spearman’s rank correlation coefficient = 0.414 (P = 0.0114). 
 
Figure 3. (A) LMP1 does not induce VEGF-C protein detected by Western blotting in 
Ad-AH cells. Lysates of Ad-AH cells transfected with pcDNA3 with or without pcLMP1 
are loaded on to corresponding lanes and examined by Western blotting with antibodies 
28 
 
to VEGF-C, LMP1, or -tubulin proteins as described in Materials and Methods. Two 
different amounts of LMP1-expression plasmid were transiently transfected. -tubulin 
was used as the loading control. (B) LMP1 does not induce VEGF-C protein secretion 
detected by ELISA in Ad-AH cells. pcDNA3 and pcLMP1 plasmids were transiently 
transfected in Ad-AH cells, and the VEGF-C concentration in supernatant of culture 
medium was measured by ELISA. The concentrations of VEGF-C in supernatant of cells 
transfected with pcDNA3 with or without pcLMP1 are shown. The results of triplicate 
experiments are shown. 
